JHEP Reports

Article	Citations
Copyright and information	233
Increased carbohydrate deficient transferrin: Whisky or candy?	149
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	94
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	85
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	83
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	83
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	79
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation	79
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score	77
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	75
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	70
Time for a globally unified chronic HBV terminology?	69
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	62
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	60
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	59
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	57
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	56
Unaddressed concerns of potential follow-up bias in the international PSC registry	54
Statistical precision of p values: A note on “Liver fibrosis progression analyzed with AI predicts renal decline”	53
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS	50
Clinical features and management for CDK4/6 inhibitor-DILI	50
Intrahepatic T cell analysis reveals Th17 and MAIT17 enrichment in primary sclerosing cholangitis	49
A small animal model of chronic hepatitis E infection using immunocompromised rats	49
Editorial Board page	49
Predicting liver ablation volumes with real-time MRI thermometry	48

Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	48
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	48
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	47
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	47
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	46
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.	45
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	44
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	44
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	43
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	43
Editorial Board page	41
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”	40
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	39
RAC1 as a novel therapeutic target for acute liver failure	38
Understanding virologic heterogeneity in chronic hepatitis B treatment	38
Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science	37
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	37
Editorial Board page	37
Loss, amplification or mistiming of the daily rhythms of metabolic markers in patients with cirrhosis	36
Development and Psychometric Evaluation of the Liver Disease Stigma Scale (LDSS)	36
Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations	36
Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways	36
Contents	35
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	35
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	35
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study	34
Deep learning can predict cardiovascular events from liver imaging	33
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	33
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	33
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	33
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	32
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	32
Macrophage MRC2 deficiency mitigates HFD-induced MASLD by downregulating CD147-regulated TNF-α production	31
Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials	31
Failure-to-rescue as a determinant of overall survival following resection for perihilar cholangiocarcinoma	31
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	30
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	30
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	30
A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium	29
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	29
Spatial proteomics and cell-cell cross-talk analysis reveal PD-L1 and IL-6 interaction in human primary sclerosing cholangitis	29
Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria	28
Contents	28
Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab	28
Editorial Board page	27
Regulatory T cell therapy in autoimmune liver disease and transplantation	27
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	27
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	26
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial	26
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis	26

Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	26
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	26
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	26
Platelets accelerate endoplasmic reticulum stress and promote hepatic steatosis	26
Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease	25
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	25
Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluation	25
Dual-tracer PET/CT in the management of hepatocellular carcinoma	25
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	25
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	25
Geography-independent mucosal microbiota alterations in primary sclerosing cholangitis persist after liver transplantation	25
The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1	24
Prognostic Significance of Pretreatment 18F-FDG PET/CT in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	24
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	24
Anatomical resection is associated with reduced early recurrences in HCC: A machine learning analysis	24
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers	24
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	24
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	24
Application of a deep learning algorithm for the diagnosis of HCC	24
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	24
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology	24
Good long-term outcomes of primary sclerosing cholangitis in childhood	23
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	23
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	23
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment	23
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	23
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	23
Does ammonia really disrupt brain oxygen homeostasis?	22
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	22
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	22
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	22
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis	22
Adipose microsomal triglyceride transfer protein deficiency protects against hepatic steatosis by upregulating PPARα activity	22
External beam radiation for HCC: Ready for incorporation into guidelines?	22
Guideline-enhanced large language models outperform physician-test takers on EASL Campus quizzes multiple choice questions	22
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors	22
Orphan drug uttroside B impedes MASH progression and HCC development in experimental models	22
Reply to: “Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria”	22
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	21
Diagnostic accuracy of transient elastography in MASLD is independent of MRI-PDFF steatosis in a multicenter study	21
Resolvin D1-mediated cellular crosstalk protects against MASH	21
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	21
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies	21
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	21
Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury	21
Elevation of liver elasticity following radiofrequency ablation reflects neutrophil-mediated abscopal effect in liver cancer	21
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	21
Acknowledging our reviewers	20
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	20
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	20
Copyright and information	20
Editorial Board page	20
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events	20
Copyright and information	20
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	20
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	20
Corrigendum to “Missed opportunities in HCV care: Trends in late diagnosis and treatment” [JHEP Reports 7 (2025) 101474]	20
Innovative approaches to the management of ascites in cirrhosis	20
Evolving epidemiology of HCC in Spain	20
Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022	20
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	20
Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]	20
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	20
The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trial	19
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	19
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	19
H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression	19
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	19
Challenges in the diagnosis and treatment of genetic cholestasis in adults	19
Spatial-quantitative profiling of intrahepatic HBsAg heterogeneity and clustered distribution in chronic HBV infection	19
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	19
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	19
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	19
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	19
Thyroid dysfunction in MASLD: Results of a nationwide study	19
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	19
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	19
The ‘social gradient' in primary liver cancer in France: A national observational study	19
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison	19
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies	18

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	18
Contents	18
Editorial Board page	18
Editorial Board page	18
Contents	18
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	18
Contents	18
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	18
Underuse of statins in MASLD despite population-based associations with lower liver stiffness	18
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	18
Reply to: “Statins in MASLD: Challenges and future directions”	18
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	18
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	17
Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development	17
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	17
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	17
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	17
Contents	17
Primary sclerosing cholangitis pathogenesis revisited: EBV-idence of immune dysregulation	16
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	16
Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infection	16
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	16
Editorial Board page	16
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?	16
Compression pressure of the external jugular vein for the assessment of intravascular volume status in decompensated cirrhosis: A pilot study	16
Spatial profiling defines three immunophenotypes and a perineural invasion-associated immune-evasion niche in gallbladder cancer	16
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	16
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	16
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	16
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	16
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	16
Accurate detection of cholangiocarcinoma in primary sclerosing cholangitis by DNA methylation biomarkers in bile and plasma	16
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	16
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	16
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	16
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	16
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study	15
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	15
A thioacrylamide-based compound directly counteracts hepatic fibrosis with profound anti-obesity action	15
Transcriptomic landscapes of effective and failed liver regeneration in humans	15
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	15
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	15
Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis	15
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	15
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	15
NTCP ubiquitination enables HBV infection	15
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC	15
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	15
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	15
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: post-hoc analysis of the ABC-01, -02 and -03 clinical trials	15
SBRT for bridging and downstaging HCC before transplant	15
Contents	15
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	15
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	15
3D endothelial cell scaffolds protect liver explants and exhibit therapeutic effects on liver fibrosis	15
Contents	15
Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway	15
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	15
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	14
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	14
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	14
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	14
Risk of portal hypertensive complications preventable by TIPS in patients with ascites	14
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	14
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	14
Copyright and information	14
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	14
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	14
Pre-liver transplant assessment of patients with acute-on-chronic liver failure: an international survey	14
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	14
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	14
Contents	14
Editorial Board page	14
Rethinking risk indices in pediatric MASLD	14
Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of porto-sinusoidal vascular disorder	13
GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis	13
A novel pharmacological inhibitor of MAP4K4 activity attenuates metabolic dysfunction-associated steatohepatitis	13
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	13
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study	13
Editorial Board page	13
Copyright and information	13
Contents	13
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	13
HEMODIAFILTRATION IMPROVES PERFORMANCE OF 24 HOUR EX SITU NORMOTHERMIC LIVER MACHINE PERFUSION	13
Drug-induced liver injury in children: A nationwide cohort study from China	13
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	13
Implementing a new HCV model of care for people who use drugs	13
Copyright and information	13
Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis	13
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α	13
Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study	13
Contents	13
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	13
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis	12
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	12